About
Who We Are
Leadership Team
Board of Directors
Clinical and Scientific Advisors
Contact
Science
Immune Continuum
CCR4 in Cancer
CCR4 in Inflammation
HPK1
Publications
Pipeline
Snapshot
FLX475
RPT193
HPK1
Discovery Programs
Investors & Media
Corporate Profile
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Email Alerts
Investor Contact
Investor FAQs
Careers
Culture
Benefits
Open Positions
PRESS RELEASES
Year
2022
2021
2020
2019
2018
Filter
May 25 | 2022
RAPT Therapeutics Announces Private Placement Financing of $50 Million
May 23 | 2022
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
May 11 | 2022
RAPT Therapeutics Reports First Quarter 2022 Financial Results
May 04 | 2022
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
March 28 | 2022
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
March 10 | 2022
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
February 09 | 2022
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference
January 04 | 2022
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
